Related Experiment Video
Updated: Jun 4, 2026
05:50
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Newer drugs for arthritis.
Canadian Family Physician Medecin De Famille Canadien
|February 11, 2011
Summary
New non-steroidal anti-inflammatory agents (NSAIA) for arthritis show limited significant advancements, with aspirin remaining a key treatment. Older drugs like penicillamine and immunosuppressants are also being reassessed for arthritis therapy.
Area of Science:
- Pharmacology
- Rheumatology
- Drug Discovery
Background:
- The primary focus for novel arthritis treatments is non-steroidal anti-inflammatory agents (NSAIA).
- Despite extensive research, no significantly safer or more effective NSAIA has emerged to surpass existing options.
- Aspirin continues to be a benchmark treatment for arthritis management.
Purpose of the Study:
- To review current advancements in non-steroidal anti-inflammatory agents for arthritis.
- To discuss the therapeutic roles of established and emerging arthritis medications.
- To evaluate the re-application of older drug classes in contemporary arthritis treatment.
Main Methods:
- Literature review of non-steroidal anti-inflammatory agents (NSAIA).
- Analysis of therapeutic applications for drugs including indomethacin, ibuprofen, naproxen, fenoprofen, and tolmetin.
- Examination of older drug classes such as penicillamine, immunosuppressants, gold compounds, and chloroquine for arthritis treatment.
Main Results:
- New non-steroidal anti-inflammatory agents (NSAIA) have not yielded major therapeutic breakthroughs.
- Established NSAIA like aspirin, indomethacin, ibuprofen, naproxen, fenoprofen, and tolmetin remain central to arthritis therapy.
- Older drugs, including penicillamine, immunosuppressants, gold, and chloroquine, are being re-evaluated for their utility in managing arthritis.
Conclusions:
- The development of novel and safe non-steroidal anti-inflammatory agents (NSAIA) for arthritis has been limited.
- Aspirin and other established NSAIA maintain significant roles in arthritis treatment.
- Revisiting older drug classes offers potential new therapeutic avenues for arthritis management.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...